Guilhem Richard

Guilhem Richard

Company: EpiVax, Inc

Job title: Chief Scientific Officer & Chief Technology Officer


Beyond Neoantigens: Optimizing Antigen Cassette Design for Enhanced Vaccine Efficacy 2:00 pm

The Ancer® neoantigen discovery platform identifies high-quality effector neoantigens, filters out inhibitory sequences, and generates string-of-beads designs for oligonucleotide-based cancer vaccines Neoantigen cassette design is a non-trivial exercise, with parameters such as number of neoantigens, ordering, and inclusion of trafficking signals having a significant impact on mRNA vaccine immunogenicity and efficacyRead more

day: Pre-Conference Focus Day

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.